Rasburicase
Top View
- Effectiveness of a Single 3-Mg Rasburicase Dose for the Management of Hyperuricemia in Patients with Hematological Malignancies
- R-CODOX-M/IVAC) Including CNS Penetration and Intensive IT Prophylaxis in HIV-Associated Burkitt’S and Atypical Burkitt’S Lymphoma
- Things We Do for No Reason™: Rasburicase for Adult Patients with Tumor Lysis Syndrome
- Fasturtec (Raburicase)
- DRUG NAME: Methotrexate
- Biopharmaceutical Benchmarks 2018
- Rasburicase for Adults with Acute Tumor Lysis Syndrome: a Review of Clinical and Cost Effectiveness and Safety
- Table III 2021 Medicare National Drug Fee Schedule
- DRUG NAME: Idarubicin
- Instructional Template for Therapeutic Protocol
- Tumor Lysis Syndrome(TLS) Treatment Guidelines
- Fasturtec, Powder for Infusion
- Chemistry Test Name: URIC ACID, PATIENT on RASBURICASE
- Is Rasburicase an Effective Alternative to Allopurinol for Management of Hyperuricemia in Renal Failure Patients? a Double Blind-Randomized Study
- Management of CKD and AKI in Malignancy
- Supportive Care in the Management of T-Cell Lymphomas
- Reduced-Dose Rasburicase (Recombinant Xanthine Oxidase) in Adult Cancer Patients with Hyperuricemia
- Therapeutic Strategies for the Treatment of Chronic Hyperuricemia: an Evidence-Based Update